Dan is an investment professional on the Frazier Life Sciences team and is involved with sourcing and evaluating new deals as well as supporting portfolio companies post-investment.
Dan joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He serves on the boards of Semnur Pharmaceuticals and Outpost Medicine. He has also been involved in Frazier’s investments in Acerta (acquired by AZ), Cidara (NASDAQ: CDTX), ProNAi (NASDAQ: DNAI), Millendo Therapeutics, Entasis, Tobira (NASDAQ: TBRA), and Precision Dermatology (acquired by Valeant).
Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy.
Dan received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases. He has authored nine papers in peer-reviewed journals and received several fellowships from the National Institutes of Health. Dan also holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.
Stanford University (B.S.)
University of Michigan (Ph.D.)